Pfizer EBITDA Margin 2010-2024 | PFE

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Pfizer (PFE) over the last 10 years. The current EBITDA margin for Pfizer as of March 31, 2024 is .
Pfizer EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $54.89B $4.32B 7.87%
2023-12-31 $58.50B $6.51B 11.13%
2023-09-30 $68.74B $15.56B 22.63%
2023-06-30 $78.15B $27.55B 35.26%
2023-03-31 $93.16B $37.45B 40.20%
2022-12-31 $100.33B $40.01B 39.88%
2022-09-30 $99.88B $38.43B 38.48%
2022-06-30 $101.28B $35.80B 35.34%
2022-03-31 $92.43B $29.32B 31.72%
2021-12-31 $81.29B $24.62B 30.29%
2021-09-30 $68.88B $22.11B 32.10%
2021-06-30 $55.12B $18.28B 33.16%
2021-03-31 $46.08B $14.63B 31.76%
2020-12-31 $41.65B $12.93B 31.05%
2020-09-30 $32.07B $7.32B 22.83%
2020-06-30 $34.47B $8.18B 23.72%
2020-03-31 $37.87B $10.70B 28.25%
2019-12-31 $40.91B $12.47B 30.47%
2019-09-30 $40.22B $11.65B 28.98%
2019-06-30 $40.84B $12.52B 30.66%
2019-03-31 $41.04B $12.27B 29.89%
2018-12-31 $40.83B $11.82B 28.96%
2018-09-30 $53.37B $20.31B 38.06%
2018-06-30 $53.24B $20.17B 37.87%
2018-03-31 $52.67B $19.94B 37.86%
2017-12-31 $52.55B $19.99B 38.04%
2017-09-30 $52.47B $19.42B 37.00%
2017-06-30 $52.35B $18.60B 35.54%
2017-03-31 $52.60B $18.15B 34.51%
2016-12-31 $52.82B $17.90B 33.89%
2016-09-30 $53.24B $17.86B 33.53%
2016-06-30 $52.29B $18.07B 34.56%
2016-03-31 $50.99B $18.00B 35.30%
2015-12-31 $48.85B $16.98B 34.76%
2015-09-30 $47.92B $17.20B 35.89%
2015-06-30 $48.20B $17.58B 36.47%
2015-03-31 $49.12B $18.16B 36.97%
2014-12-31 $49.61B $18.79B 37.87%
2014-09-30 $50.05B $19.84B 39.64%
2014-06-30 $50.33B $20.34B 40.41%
2014-03-31 $50.53B $20.88B 41.32%
2013-12-31 $51.58B $21.59B 41.86%
2013-09-30 $50.88B $21.73B 42.71%
2013-06-30 $51.19B $21.62B 42.24%
2013-03-31 $52.18B $22.25B 42.64%
2012-12-31 $54.66B $22.92B 41.93%
2012-09-30 $53.25B $22.62B 42.49%
2012-06-30 $56.90B $23.53B 41.35%
2012-03-31 $59.42B $23.26B 39.14%
2011-12-31 $61.04B $22.99B 37.67%
2011-09-30 $65.06B $22.42B 34.45%
2011-06-30 $64.44B $22.10B 34.30%
2011-03-31 $65.09B $22.25B 34.18%
2010-12-31 $65.17B $21.81B 33.47%
2010-09-30 $65.50B $19.75B 30.16%
2010-06-30 $61.13B $18.86B 30.86%
2010-03-31 $54.98B $16.57B 30.15%
2009-12-31 $49.27B $15.72B 31.90%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $163.651B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $767.386B 110.91
Novo Nordisk (NVO) Denmark $610.484B 46.91
Johnson & Johnson (JNJ) United States $353.710B 14.05
Merck (MRK) United States $327.973B 59.67
AbbVie (ABBV) United States $277.347B 14.33
AstraZeneca (AZN) United Kingdom $243.511B 21.17
Novartis AG (NVS) Switzerland $205.483B 14.57
Sanofi (SNY) $122.796B 11.59
Innoviva (INVA) United States $0.985B 6.92